Dermata Therapeutics Inc (DRMA) Annual Income Statement (USD)
DRMA Quarterly Financials (USD)
Frequently Asked Questions About Dermata Therapeutics Inc (DRMA) Stock
Dermata Therapeutics Inc's (DRMA) last reported annual revenue was USD 0.00.
Dermata Therapeutics Inc's (DRMA) annual revenue growth rate based on the revenue reported in the past 5 years is : N/A
Dermata Therapeutics Inc's(DRMA) is not profitable as of its last reported annual financials.
The net profit margin for Dermata Therapeutics Inc's(DRMA) from its laster reported year is N/A
The return on equity (ROE) for Dermata Therapeutics Inc's(DRMA) from its last reported annual financials is : -125.96%
The return on assets (ROA) for Dermata Therapeutics Inc's(DRMA) from its last reported annual financials is : -67.36%
The return on invested capital (ROIC) for Dermata Therapeutics Inc's(DRMA) from its last reported annual financials is : -129.95%
The Debt to Equity ratio for Dermata Therapeutics Inc's(DRMA) from its last reported annual financials is : 0.00%
The dividend yield for Dermata Therapeutics Inc's(DRMA) from its laster reported year is 0.00%
Dermata Therapeutics Inc's(DRMA) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for DRMA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
